alendronate has been researched along with Compression Fractures in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "From January 2018 to January 2020, we recruited 165 female osteoporosis patients after percutaneous vertebroplasty who were assigned into sequential treatment of teriparatide followed by alendronate group (TPTD + ALN group) and alendronate alone group (ALN group)." | 8.31 | Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study. ( Han, W; Huang, K; Long, Y; Tan, J; Wang, M; Yang, D; Yi, W; Zeng, S; Zhu, S, 2023) |
| " The primary measures of romosozumab efficacy used in this study were vertebral, non-vertebral, and clinical fracture events, and secondary outcomes were bone mineral density (BMD) changes at the lumbar spine, total hip, and femoral neck and the incidence of adverse events (AEs), RESULTS: Nine RCTs including 12 796 participants were included in the analysis, and romosozumab was compared with placebo, alendronate, and teriparatide in the treatment of osteoporosis in postmenopausal women." | 5.41 | Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J). ( Guo, S; Huang, W; Nagao, M; Nishizaki, Y; Tanigawa, T; Yonemoto, N, 2023) |
| "From January 2018 to January 2020, we recruited 165 female osteoporosis patients after percutaneous vertebroplasty who were assigned into sequential treatment of teriparatide followed by alendronate group (TPTD + ALN group) and alendronate alone group (ALN group)." | 4.31 | Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study. ( Han, W; Huang, K; Long, Y; Tan, J; Wang, M; Yang, D; Yi, W; Zeng, S; Zhu, S, 2023) |
| "He was subsequently diagnosed to have osteopenia with a bone mineral density T-score of -1." | 1.35 | Vertebral fracture in a pilot during centrifuge training: finding of osteopenia. ( Loh, A; Low, R; Ooi, A; Teoh, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, W | 1 |
| Nagao, M | 1 |
| Yonemoto, N | 1 |
| Guo, S | 1 |
| Tanigawa, T | 1 |
| Nishizaki, Y | 1 |
| Yang, D | 1 |
| Tan, J | 1 |
| Long, Y | 1 |
| Huang, K | 1 |
| Han, W | 1 |
| Wang, M | 1 |
| Zhu, S | 1 |
| Zeng, S | 1 |
| Yi, W | 1 |
| Jia, P | 1 |
| Wang, R | 1 |
| Yuan, J | 1 |
| Chen, H | 1 |
| Bao, L | 1 |
| Feng, F | 1 |
| Tang, H | 1 |
| Iwata, A | 1 |
| Kanayama, M | 1 |
| Oha, F | 1 |
| Hashimoto, T | 1 |
| Iwasaki, N | 1 |
| Zhao, Y | 1 |
| Xue, R | 1 |
| Shi, N | 1 |
| Xue, Y | 1 |
| Zong, Y | 1 |
| Lin, W | 1 |
| Pei, B | 1 |
| Sun, C | 1 |
| Fan, R | 1 |
| Jiang, Y | 1 |
| Low, R | 1 |
| Teoh, T | 1 |
| Loh, A | 1 |
| Ooi, A | 1 |
| Tseng, YY | 1 |
| Su, CH | 1 |
| Lui, TN | 1 |
| Yeh, YS | 1 |
| Yeh, SH | 1 |
2 reviews available for alendronate and Compression Fractures
| Article | Year |
|---|---|
Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J).
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Compression; Humans; | 2023 |
A case of pregnancy and lactation-associated osteoporosis and a review of the literature.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium Carbonate; Drug Therapy, | 2020 |
2 trials available for alendronate and Compression Fractures
| Article | Year |
|---|---|
Aggravation of spinal cord compromise following new osteoporotic vertebral compression fracture prevented by teriparatide in patients with surgical contraindications.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cont | 2016 |
Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Combined Modal | 2012 |
3 other studies available for alendronate and Compression Fractures
| Article | Year |
|---|---|
Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Compression; Humans; | 2023 |
Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Fracture Healing; Fr | 2017 |
Vertebral fracture in a pilot during centrifuge training: finding of osteopenia.
Topics: Adult; Aerospace Medicine; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; | 2008 |